C-RZPYLento Bio
small molecules, lens repair, eye drops
repairingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RZPY
C-RZPYC-RZPYsmall molecules, lens repair, eye drops
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Lento Bio states that chronic diseases of aging can be treated by restoring tissue flexibility and function through small molecules that directly target underlying molecular damage. Its stated focus is on removing Advanced Glycation End Products (AGEs), beginning with AGE-related damage in the ocular lens to treat presbyopia, while also pursuing broader applications in systemic age-related disease.
SourceLentoBio states that chronic diseases of aging can be treated by restoring tissue flexibility and function through small-molecule therapies that directly target molecular damage. The company emphasizes effective, safe, and durable treatments, with an initial focus on removing Advanced Glycation End Products (AGEs), especially lens damage causing presbyopia, while also exploring broader systemic disease applications.
SourceLento Bio states that chronic age-related diseases can be treated by directly targeting molecular damage with small molecules, with a primary emphasis on removing Advanced Glycation End Products (AGEs) to restore tissue flexibility and function. The company presents this as an approach to develop effective, safe, and durable treatments, beginning with damage to the lens in presbyopia and potentially extending to systemic disease.
Source